News
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 5, 2023: SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, is announcing a strategic commercial...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), November 6, 2023: — SkylineDx, an innovative molecular diagnostics company, is pleased to announce the forthcoming presentation of an impactful poster by Dr M.E. Egger at...
Real World Prospective Study shows clinical implementation of Merlin Assay (CP-GEP) in melanoma care
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October 31, 2023: SkylineDx an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, proudly announces the successful clinical...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), September 28, 2023: SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, announced that a new peer-reviewed...
ROTTERDAM, Netherlands and SAN DIEGO, U.S. April 20, 2023: SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced its first non-academic...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 17, 2023: SkylineDx, an innovative diagnostics company, focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced the publication of...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), September 1, 2022: Today, SkylineDx, a leading molecular diagnostics company, announces the commercial launch of Merlin Assay as CE-IVD distributable test kit in Europe. Merlin Assay...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), May 25, 2022: Today, SkylineDx, a leading molecular diagnostics company, announces Medicare coverage for Merlin Test. The local coverage determination was issued under the foundational policy...
ROTTERDAM (the Netherlands), SAN DIEGO (USA), April 26, 2022: Today, SkylineDx, a leading molecular diagnostics company, announced the addition of new leadership to reinforce their commitment to bringing personalized diagnostics to the...
ROTTERDAM (the Netherlands), SAN DIEGO (USA), April 21, 2022: Today, SkylineDx presents new data showing that their Merlin Test was able to prospectively reduce >37% of surgeries in a non-interventional study for newly...
ROTTERDAM (the Netherlands), SAN DIEGO (USA), February 24, 2022: today, SkylineDx announced that their Merlin Test for melanoma patients would have been able to reduce over 59% of surgery-related complications by means of...
ROTTERDAM (the Netherlands), SAN DIEGO (US), GHENT (Belgium), December 22, 2021: Today, SkylineDx announced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on...
ROTTERDAM (the Netherlands), SAN DIEGO (USA), December 21, 2021: today, SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux’ largest biotech investors...
ROTTERDAM (the Netherlands), SAN DIEGO (California, US), November 9, 2021: today, SkylineDx announced that the Accreditation Committee of the College of American Pathologists (CAP) has renewed accreditation to SkylineDx’ laboratory in San Diego, California...
ROTTERDAM (the Netherlands), SAN DIEGO (US), October 12, 2021: today, SkylineDx announced it has entered into an exclusive patent license agreement with Imperial College London for the worldwide development and commercialization of a...
ROTTERDAM (the Netherlands), SAN DIEGO (US), June 24, 2021: Today, SkylineDx announced to invest in research and development in the field of Squamous Cell Carcinoma (SCC), as part of a Dutch consortium including...
ROTTERDAM (the Netherlands), SAN DIEGO (US), June 10, 2021: Today, SkylineDx announced that the first hospitals will start including melanoma patients in a large prospective clinical study in the United States, to validate...
ROTTERDAM (the Netherlands), SAN DIEGO (US), April 30, 2021: SkylineDx announced that the performance of their melanoma diagnostic test (Merlin Assay) is confirmed in an independent group of U.S. patients from the Mayo...
